Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Drug Details

General Information of the Drug (ID: DR1642)
Name
Pinostrobin
Synonyms
Pinostrobin; 480-37-5; Pinostrombin; Pinocembrin-7-methylether; UNII-SZD9LZS694; SZD9LZS694; CHEMBL254613; (S)-2,3-Dihydro-5-hydroxy-7-methoxy-2-phenyl-4-benzopyrone; CHEBI:80491; (2s)-5-hydroxy-7-methoxyflavanone; 5-Hydroxy-7-methoxy-2-phenyl-2,3-dihydro-4H-chromen-4-one; (2S)-5-hydroxy-7-methoxy-2-phenyl-2,3-dihydrochromen-4-one; pinocembrin-7-methyl ether; dihydrotectochrysin; (-)-pinostrobin; (2S)-pinostrobin; (2S)-5-hydroxy-7-methoxy-2-phenyl-chroman-4-one; SCHEMBL7648566; DTXSID50963979; ZINC391894; Pinostrobin, >=99.0% (TLC); HY-N2127; EINECS 207-548-1; BDBM50338968; (+/-)-5-hydroxy-7-methoxyflavanone; AKOS037515398; CCG-262304; NCGC00163610-01; 5-Hydroxy-7-methoxy-2-phenyl-chroman-4-one; CS-0018678; C16419; 480P375; SR-05000013704; SR-05000013704-1; Q27149542; 5-Hydroxy-7-methoxy-2-phenyl-2,3-dihydro-4H-1-benzopyran-4-one; (2S)-5-hydroxy-7-methoxy-2-phenyl-2,3-dihydro-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 2,3-dihydro-5-hydroxy-7-methoxy-2-phenyl-, (S)-
    Click to Show/Hide
Molecular Type
Small molecule
Disease Parkinson's disease [ICD-11: 8A00] Investigative [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C16H14O4
PubChem CID
73201
Canonical SMILES
COC1=CC(=C2C(=O)CC(OC2=C1)C3=CC=CC=C3)O
InChI
1S/C16H14O4/c1-19-11-7-12(17)16-13(18)9-14(20-15(16)8-11)10-5-3-2-4-6-10/h2-8,14,17H,9H2,1H3/t14-/m0/s1
InChIKey
ORJDDOBAOGKRJV-AWEZNQCLSA-N
CAS Number
CAS 480-37-5
ChEBI ID
CHEBI:80491
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Acacetin      Acacia farnesiana     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model MDA-MB-231 CVCL_0062 Breast adenocarcinoma Homo sapiens
T-47D CVCL_0553 Invasive breast carcinoma Homo sapiens
                    Experimental
                    Result(s)
Acacetin and Pinostrobin inhibit malignant breast epithelial cell adhesion and focal adhesion formation to attenuate cell migration.
Target and Pathway
Target(s) Hexokinase-2 (HK2)  Molecule Info  [3]
KEGG Pathway Glycolysis/Gluconeogenesis Click to Show/Hide
2 Fructose and mannose metabolism
3 Galactose metabolism
4 Starch and sucrose metabolism
5 Amino sugar and nucleotide sugar metabolism
6 Neomycin, kanamycin and gentamicin biosynthesis
7 Metabolic pathways
8 Carbon metabolism
9 HIF-1 signaling pathway
10 Insulin signaling pathway
11 Type II diabetes mellitus
12 Carbohydrate digestion and absorption
13 Central carbon metabolism in cancer
References
Reference 1 Pinostrobin Exerts Neuroprotective Actions in Neurotoxin-Induced Parkinson's Disease Models through Nrf2 Induction. J Agric Food Chem. 2018 Aug 8;66(31):8307-8318.
Reference 2 Acacetin and Pinostrobin Inhibit Malignant Breast Epithelial Cell Adhesion and Focal Adhesion Formation to Attenuate Cell Migration. Integr Cancer Ther. Jan-Dec 2020;19:1534735420918945.
Reference 3 3-Bromopyruvate: targets and outcomes. J Bioenerg Biomembr. 2012 Feb;44(1):7-15.
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China